EP2069376A4 - Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions - Google Patents
Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositionsInfo
- Publication number
- EP2069376A4 EP2069376A4 EP07861332.0A EP07861332A EP2069376A4 EP 2069376 A4 EP2069376 A4 EP 2069376A4 EP 07861332 A EP07861332 A EP 07861332A EP 2069376 A4 EP2069376 A4 EP 2069376A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- peptide
- nucleic acid
- influenza virus
- immune responses
- cellular immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83211206P | 2006-07-21 | 2006-07-21 | |
PCT/US2007/016529 WO2008039267A2 (en) | 2006-07-21 | 2007-07-23 | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2069376A2 EP2069376A2 (en) | 2009-06-17 |
EP2069376A4 true EP2069376A4 (en) | 2013-10-16 |
Family
ID=39230737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07861332.0A Withdrawn EP2069376A4 (en) | 2006-07-21 | 2007-07-23 | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2069376A4 (en) |
AU (1) | AU2007300663A1 (en) |
CA (1) | CA2658559A1 (en) |
WO (1) | WO2008039267A2 (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2170365T3 (en) | 2007-06-25 | 2017-03-31 | The Administrators Of The Tulane Educational Fund | Influenza inhibiting compositions and methods |
WO2009016639A2 (en) * | 2007-08-02 | 2009-02-05 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope influenza vaccines |
EP2296688A2 (en) * | 2007-10-26 | 2011-03-23 | Glykos Finland Oy | Peptide vaccine for influenza virus |
FI20080333A0 (en) * | 2008-05-02 | 2008-05-02 | Glykos Finland Oy | Influenza virus nucleic acids and peptides |
RU2528750C2 (en) * | 2008-11-19 | 2014-09-20 | Лабораторио Ави-Мекс, С.А. Де С.В. | Recombinant vaccine of inactivated viral vector |
US8282938B2 (en) | 2008-11-28 | 2012-10-09 | National Institute Of Infectious Diseases | Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain |
EP2391635B1 (en) | 2009-01-28 | 2017-04-26 | Epimmune Inc. | Pan-dr binding polypeptides and uses thereof |
WO2010088393A2 (en) * | 2009-01-28 | 2010-08-05 | Antigen Express, Inc. | Li-kay hybrid peptides that modulate the immune response to influenza |
CN101792745B (en) * | 2009-02-04 | 2014-09-17 | 中国科学院生物物理研究所 | Expression and purification of influenza virus polymerase PA N-terminal polypeptide and crystal structure thereof |
CN101565455B (en) * | 2009-05-25 | 2012-03-14 | 中国科学院微生物研究所 | CTL epitope polypeptides of bird flu H5N1 virus and applications thereof |
CA2761733C (en) * | 2009-06-01 | 2019-01-08 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Reagents and methods for detecting influenza virus proteins |
RU2012107702A (en) | 2009-07-31 | 2013-09-10 | Пэксвэкс, Инк. | ADENOVIRUS VECTORS |
WO2011041490A1 (en) * | 2009-09-30 | 2011-04-07 | Saint Louis University | Peptides for inducing heterosubtypic influenza t cell responses |
CN102153621B (en) * | 2010-02-12 | 2014-07-02 | 广东省疾病预防控制中心 | B-cell epitope of NA-protein for new influenza A (H1N1) and application thereof |
CN102892778B (en) * | 2010-02-19 | 2018-06-08 | 列日大学 | For treating polynucleotides, albumen and the transgenic animals of the disease of influenza A virus induction, the modified Mx albumen of coding |
WO2011138032A2 (en) * | 2010-05-05 | 2011-11-10 | Artemev, Timur | Universal influenza vaccines and methods for their generation |
WO2012040127A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
AU2011360572B2 (en) | 2011-02-22 | 2017-03-02 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
US20140302124A1 (en) * | 2011-10-19 | 2014-10-09 | Immunotape, Inc. | Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION |
US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
WO2013093514A2 (en) * | 2011-12-23 | 2013-06-27 | Retroscreen Virology Ltd | Vaccines - peptides |
NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
WO2014108515A1 (en) * | 2013-01-10 | 2014-07-17 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof |
CN103333224B (en) * | 2013-05-10 | 2015-03-25 | 中国农业科学院哈尔滨兽医研究所 | Avian influenza virus NS1 protein B cell epitope polypeptide and applications thereof |
WO2015186721A1 (en) * | 2014-06-03 | 2015-12-10 | 国立研究開発法人農業・食品産業技術総合研究機構 | Antibody or antibody fragment including variable region thereof, antigen polypeptide, and uses thereof |
BR112019013402A2 (en) | 2016-12-28 | 2020-03-03 | Invvax, Inc. | INFLUENCE VACCINES |
CN106589105B (en) * | 2017-01-23 | 2020-09-15 | 中国医科大学 | HLA-A2-restricted ECM 1-specific CTL epitope peptide and application thereof |
WO2019046901A1 (en) * | 2017-09-08 | 2019-03-14 | The University Of Melbourne | Methods and compositions for preventing influenza infection |
US20220118077A1 (en) * | 2018-09-11 | 2022-04-21 | Shanghai Public Health Clinical Center | Immunogen for broad-spectrum influenza vaccine and application thereof |
WO2021255221A1 (en) * | 2020-06-19 | 2021-12-23 | Intervet International B.V. | Swine influenza a virus vaccine comprising a nucleic acid construct encoding antigens of specific virus lineages |
WO2021255225A1 (en) * | 2020-06-19 | 2021-12-23 | Intervet International B.V. | Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus |
WO2022032274A1 (en) * | 2020-08-02 | 2022-02-10 | Richard Ascione | Vaccine compositions for influenza viruses and methods of use |
JP2023541807A (en) * | 2020-08-25 | 2023-10-04 | ジェネンテック, インコーポレイテッド | Assays and reagents for characterizing MHCI peptide binding |
CN116410271A (en) * | 2023-03-13 | 2023-07-11 | 华南农业大学 | H5N1 subtype AIV MHC B1 restricted T cell epitope peptide and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060153871A1 (en) * | 2005-01-11 | 2006-07-13 | Olsen Christopher W | H3 equine influenza A virus |
-
2007
- 2007-07-23 CA CA002658559A patent/CA2658559A1/en not_active Abandoned
- 2007-07-23 AU AU2007300663A patent/AU2007300663A1/en not_active Abandoned
- 2007-07-23 EP EP07861332.0A patent/EP2069376A4/en not_active Withdrawn
- 2007-07-23 WO PCT/US2007/016529 patent/WO2008039267A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060153871A1 (en) * | 2005-01-11 | 2006-07-13 | Olsen Christopher W | H3 equine influenza A virus |
Non-Patent Citations (11)
Title |
---|
ALEXANDER J ET AL: "Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 71, no. 5, 1 May 2010 (2010-05-01), pages 468 - 474, XP027006096, ISSN: 0198-8859, [retrieved on 20100310] * |
EBERL GERARD ET AL: "Immunodominance of cytotoxic T lymphocyte epitopes co-injected in vivo and modulation by interleukin-12", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 26, no. 11, 1996, pages 2709 - 2716, XP055244817, ISSN: 0014-2980 * |
EPSTEIN SUZANNE L ET AL: "DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice", EMERGING INFECTIOUS DISEASES, vol. 8, no. 8, August 2002 (2002-08-01), pages 796 - 801, XP002712185, ISSN: 1080-6040 * |
FRUCI D ET AL: "Anchor residue motifs of HLA class I-binding peptides analysed by the direct binding of synthetic peptides to HLA class I alpha chains", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 36, no. 1, 1 January 1993 (1993-01-01), pages 67, XP023851425, ISSN: 0198-8859, [retrieved on 19930101], DOI: 10.1016/0198-8859(93)90104-9 * |
GIANFRANI C ET AL: "Human memory CTL response specific for influenza A virus is broad and multispecific", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 61, no. 5, 1 May 2000 (2000-05-01), pages 438 - 452, XP002492007, ISSN: 0198-8859, DOI: 10.1016/S0198-8859(00)00105-1 * |
GUERCIO DEL M-F ET AL: "BINDING OF A PEPTIDE ANTIGEN TO MULTIPLE HLA ALLELES ALLOWS DEFINITION OF AN A2-LIKE SUPERTYPE", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 154, 1 January 1995 (1995-01-01), pages 685 - 693, XP002055570, ISSN: 0022-1767 * |
ISHIOKA G Y ET AL: "UTILIZATION OF MHC CLASS I TRANSGENIC MICE FOR DEVELOPMENT OF MINIGENE DNA VACCINES ENCODING MULTIPLE HLA-RESTRICTED CTL EPITOPES", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 162, no. 7, 1 April 1999 (1999-04-01), pages 3915 - 3925, XP000872894, ISSN: 0022-1767 * |
KUBO R T ET AL: "DEFINITION OF SPECIFIC PEPTIDE MOTIFS FOR FOUR MAJOR HLA-A ALLELES", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 152, no. 8, 1 January 1994 (1994-01-01), pages 3913 - 3924, XP002936662, ISSN: 0022-1767 * |
LIVINGSTON B D ET AL: "Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines", VACCINE, ELSEVIER LTD, GB, vol. 19, no. 32, 14 September 2001 (2001-09-14), pages 4652 - 4660, XP004303157, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(01)00233-X * |
SIDNEY J ET AL: "SPECIFICITY AND DEGENERACY IN PEPTIDE BINDING TO HLA-B7-LIKE CLASS I MOLECULES", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 157, no. 8, 15 October 1996 (1996-10-15), pages 3480 - 3490, XP002055572, ISSN: 0022-1767 * |
THRELKELD S C ET AL: "Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 AUG 1997, vol. 159, no. 4, 15 August 1997 (1997-08-15), pages 1648 - 1657, XP002712184, ISSN: 0022-1767 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008039267A2 (en) | 2008-04-03 |
EP2069376A2 (en) | 2009-06-17 |
AU2007300663A1 (en) | 2008-04-03 |
CA2658559A1 (en) | 2008-04-03 |
WO2008039267A3 (en) | 2008-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2069376A4 (en) | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions | |
EP2023952A4 (en) | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions | |
EP1732598A4 (en) | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions | |
IL239023A0 (en) | Neutralizing antibodies to influenza viruses | |
EP2066339A4 (en) | Compositions and methods of enhancing immune responses | |
EP2442829A4 (en) | Structured viral peptide compositions and methods of use | |
PL1976559T3 (en) | Influenza vaccines containing hemagglutinin and matrix proteins | |
BRPI1012811A2 (en) | herpes simplex virus type 2 vaccines: compositions and methods for obtaining an immune response | |
EP2089053A4 (en) | Hpv antigen fusion protein vaccine compositions and uses thereof | |
EP2414545A4 (en) | Nucleic acid preparation compositions and methods | |
KR101790354B9 (en) | 32 human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof | |
IL215451A (en) | Antigenic constructs comprising an antigenic peptide of the tau protein and pharmaceutical compositions comprising same | |
EP1984405A4 (en) | Influenza antigens, vaccine compositions, and related methods | |
HK1223968A1 (en) | Rabies virus and compositions and methods thereof | |
FI20060946A0 (en) | Influenza virus nucleic acids and peptides | |
GB0922209D0 (en) | Proteins, nucleic acid molecules and compositions | |
AP2008004625A0 (en) | Avian influenza viruses, vaccines, compositions, formulations, and methods | |
HK1123055A1 (en) | Hepatitis c virus nucleic acid vaccine | |
IL215955A (en) | Uracyl spirooxetane nucleosides, compositions comprising them and uses thereof as hcv inhibitors | |
HK1112846A1 (en) | Canine influenza virus and related compositions and methods of use | |
EP1885173A4 (en) | Chloroplasts engineered to express pharmaceutical proteins | |
IL212545A (en) | Isolated antibodies binding tlr3 and pharmaceutical compositions comprising them | |
IL213189A0 (en) | Recombinant avian influenza vaccine and uses thereof | |
IL217709A (en) | Recombinant adenoviruses, pharmaceutical compositions and vaccines comprising them and uses thereof in inducing cellular and humoral immune response | |
BRPI1006863A2 (en) | vaccine and purified plasmodium compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
17P | Request for examination filed |
Effective date: 20090630 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1135403 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20130917 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/005 20060101ALI20130906BHEP Ipc: C07H 21/02 20060101AFI20130906BHEP |
|
17Q | First examination report despatched |
Effective date: 20160201 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20160614 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1135403 Country of ref document: HK |